6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2024

Commission File Number: 001-39374

Inventiva S.A. (Translation of registrant's name into English)

50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ]

On December 12, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated December 12, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EdgarFiling

EXHIBIT 99.1

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’ Meeting.

The Combined Shareholders' Meeting was held on Wednesday December 11, 2024, at 9 a.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva.

Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Eric Duranson, as secretary of the general meeting.

All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 59^th^ resolution, which had been the subject of a negative recommendation by the Board of Directors. The 59^th^ resolution would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.

Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for corporate officers as presented in the report of the Board of Directors (Schedules 1 to 4, pages 27 and seq.).

Information on the results of the votes is detailed below:

• Total number of shares composing the share capital: 87 077 695
• Total number of shares with voting rights: 86 962 703

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal phase 3 clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).

www.inventivapharma.com

Contacts

Important Notice

This press release contains “forward-looking statements” within the meaning of the safe harbor provisionsof the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this pressrelease are forward-looking statements.

These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinicalprograms and clinical trials, including design, duration, timing, recruitment costs, screening and enrollment for those trials, includingthe ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH, clinical trial data releases and publications, the information,insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product candidates,including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinicaland clinical development plans, the expected benefit of having received Breakthrough Therapy Designation, including its impact on thedevelopment and review timeline of Inventiva’s product candidates, the potential development of and regulatory pathway for odiparcil,and future activities, expectations, plans, growth and prospects of Inventiva and its partners. Certain of these statements, forecastsand estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”,“intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”,“could”, “might”, “should”, “designed”, “hopefully”, “target”,“potential”, “opportunity”, “possible”, “aim”, and “continue” and similarexpressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statementsthat are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statementsand involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materiallyfrom those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyondInventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be availableon their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive thenecessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expectedtimeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievementsexpressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva cannot provideassurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the resultsor timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approvedproducts and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operatinghistory and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, inthe absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or developmentprograms or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue asa going concern, Inventiva’s ability to obtain financing and to enter into potential transactions, Inventiva's future success isdependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future productcandidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva'sand its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectationswith respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’sclinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASHmay not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delaysbeyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities,the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients inclinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factorsoutside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other propertiesthat could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition andInventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial conditionand results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraineand related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, healthepidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptionsin banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-lookingstatements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of thispress release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autoritédes Marchés Financiers on April 3, 2024 as amended on October 14, 2024, and the Annual Report on Form 20-F for the year ended December31, 2023, filed with the Securities and Exchange Commission on April 3, 2024, and the Half-Year Report for the six months ended June 30,2024 on Form 6-K filed with the SEC on October 15, 2024. Other risks and uncertainties of which Inventiva is not currently aware may alsoaffect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is underno obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for anyconsequences arising from the use of any of the above statements.

Attachment

• Inventiva - PR - Results of GM 11 12 2024 - EN - 12 12 2024 (https://ml-eu.globenewswire.com/Resource/Download/b1f1edce-73f5-437d-a1c7-499b334253dd)